At PatientWing, we follow the science that's changing medicine. This week's research is exciting. Scientists may have found a way to repair MS nerve damage. A new pill is helping people with stubborn high blood pressure. And a 4-week diet study made people biologically younger. Here's what they found.
Multiple sclerosis (MS) affects nearly three million people worldwide. It's one of the top causes of disability in young adults. Today's MS treatments slow attacks on the brain and spinal cord. But they can't fix damage already done.
That gap is a major frustration in MS care. New research from the University of Helsinki suggests scientists may be closing it.
Researcher Tapani Koppinen, in Associate Professor Merja Voutilainen's group, found two drug molecules. Both triggered the regrowth of myelin, the protective coating around nerve fibers. Myelin acts like insulation around a wire, helping nerves send signals properly. In MS, the immune system slowly destroys it. If it could be rebuilt, nerve signaling could be restored.
The two drugs work in different ways. The first blocks a stress signal that gets stuck in MS-damaged brain tissue, freeing repair cells to do their job. The second changes the scar tissue around damaged areas that normally blocks nerve repair.
Despite working differently, both produced similar results: real myelin regrowth and less brain inflammation in MS-like tissue.
This is still early-stage. The research was done in animals and lab models, not people. Human MS is more complex, and any brain drug must cross the blood-brain barrier, which blocks most substances. Encouragingly, both molecules reached the central nervous system in animal tests.
The next step is clinical trials. If they work in people, MS patients could one day have the first treatment that rebuilds what the disease destroys, not just slows it.
📰 Read more: SciTechDaily / University of Helsinki, May 2026
For many people with chronic kidney disease, managing high blood pressure is an ongoing and losing battle. Blood pressure and kidney function are tied together in a difficult cycle: high blood pressure damages the kidneys, and declining kidney function makes blood pressure harder to control. Over time, that cycle raises the risk of heart attack, stroke, heart failure, and kidney failure.
A new drug called baxdrostat may help break that cycle.
In a Phase 2 clinical trial published in the Journal of the American Society of Nephrology, researchers added baxdrostat to the standard medications already being taken by 195 patients with chronic kidney disease and uncontrolled high blood pressure. At the start of the trial, participants had an average systolic blood pressure of 151 mm Hg despite already being on treatment.
After 26 weeks, those taking baxdrostat saw their systolic blood pressure drop by an average of 8.1 mm Hg more than the placebo group, about a 5% reduction. That may sound modest, but the kidney protection signal was striking: a marker in the urine tied to kidney and cardiovascular damage was 55% lower in the baxdrostat group, suggesting the drug may be doing more than just lowering blood pressure numbers.
Baxdrostat works by blocking an enzyme that produces aldosterone, a hormone made by the adrenal glands. When aldosterone is too high or poorly regulated, it causes the body to hold onto sodium and water, which pushes blood pressure up. By dialing that hormone down, baxdrostat appears to relieve pressure on both the heart and the kidneys at once.
The drug has not been approved yet, but two large Phase 3 trials are now underway to test its effects over a longer period. The results so far are being called potentially game-changing for this patient population.
📰 Read more: SciTechDaily / Journal of the American Society of Nephrology, May 2026
When we talk about aging, we usually mean the number of birthdays we've had. But scientists have a second way to measure age: biological age, which reflects how well the body is actually functioning at a cellular and molecular level based on things like cholesterol, insulin, and inflammation markers. Two people who are both 70 years old can have very different biological ages depending on their health and habits.
A new study from the University of Sydney, published in the journal Aging Cell, found that in adults aged 65 to 75, just four weeks of specific dietary changes was enough to measurably lower their biological age scores.
The study enrolled 104 participants and randomly assigned them to one of four diets. Three of the four groups showed a reduction in biological age over the four weeks. The exception was the group eating closest to their existing habits, specifically a higher-fat, lower-carb omnivorous diet. The strongest results came from a lower-fat, higher-carbohydrate diet. Participants who shifted toward more plant-based protein, reducing animal-based foods, also showed improvement.
Researchers were careful about how far they took these findings. They were clear that the study does not prove that dietary changes extend lifespan or reduce the risk of age-related disease. Biological age scores can shift for a number of reasons, and it's not yet known whether changes this short-lived translate to lasting health benefits. The researchers are calling for longer studies to find out.
But what caught scientists' attention is the speed. Four weeks is a very short window, and the fact that measurable changes to aging biomarkers appeared that quickly suggests the body is more responsive to what we eat than many assumed. As lead researcher Dr. Caitlin Andrews put it, the findings offer an early indication of the potential benefits of dietary changes later in life. That's worth paying attention to.
📰 Read more: ScienceDaily / Aging Cell, May 2026
This week's research touches something that comes up again and again in patient communities: the frustration with treatments that only slow things down but can't reverse what's already happened. Both the MS remyelination work and the kidney-blood pressure study are pointing toward a future where medicine does more than manage damage. And the diet and aging study is a reminder that the body has more capacity to respond and adapt than we often give it credit for, sometimes faster than we'd expect.
Come back next week for another edition of The Weekly Wing. 💚
Curious what breakthroughs like these look like from the patient side? Our Patient Stories collection features advocates sharing their journeys, what helped them, and what they wish they'd known earlier. Find one that speaks to you.
For more on what's next in medicine, head on to the PatientWing Blog for more pieces on new discoveries.
